Bio-Rad Laboratories (BIO) News Today → Dems have chosen Biden replacement? (From Paradigm Press) (Ad) Free BIO Stock Alerts $286.86 +4.85 (+1.72%) (As of 05/31/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative June 1 at 5:37 AM | marketbeat.comFranklin Resources Inc. Cuts Holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO)Franklin Resources Inc. cut its position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 27.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 19,000 shares of the medical research company's stock after selling 7,3May 31 at 3:43 PM | marketbeat.comBio-Rad Laboratories, Inc. (NYSE:BIO) Shares Purchased by Parnassus Investments LLCParnassus Investments LLC boosted its position in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 7.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 237,790 shares of the medical research company's stock after aMay 31 at 8:41 AM | marketbeat.comBio-Rad Laboratories, Inc. (NYSE:BIO) Expected to Post Q2 2025 Earnings of $2.64 Per ShareBio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) - Equities research analysts at Zacks Research boosted their Q2 2025 EPS estimates for Bio-Rad Laboratories in a note issued to investors on Tuesday, May 28th. Zacks Research analyst R. Anand now expects that the medical research company will poMay 30 at 9:00 AM | businesswire.comBio-Rad Names Anette Engelhardt Executive Vice President and President of Clinical Diagnostics GroupMay 30 at 5:42 AM | americanbankingnews.comZacks Research Weighs in on Bio-Rad Laboratories, Inc.'s Q2 2024 Earnings (NYSE:BIO)May 29 at 11:44 PM | marketbeat.comFirst Pacific Advisors LP Acquires New Stake in Bio-Rad Laboratories, Inc. (NYSE:BIO)First Pacific Advisors LP acquired a new stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 4,866 shares of the medical research company's stock, valued at approximatelyMay 28, 2024 | marketbeat.comBio-Rad Laboratories Q1 Earnings TranscriptMay 28, 2024 | americanbankingnews.comBio-Rad Laboratories (NYSE:BIO) Upgraded by StockNews.com to BuyMay 28, 2024 | marketbeat.comBio-Rad Laboratories (NYSE:BIO) Upgraded to "Buy" at StockNews.comStockNews.com upgraded Bio-Rad Laboratories from a "hold" rating to a "buy" rating in a research report on Tuesday.May 27, 2024 | marketbeat.com226,523 Shares in Bio-Rad Laboratories, Inc. (NYSE:BIO) Acquired by Norges BankNorges Bank purchased a new position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 226,523 shares of the medical research company's stock, vaMay 26, 2024 | marketbeat.comWestfield Capital Management Co. LP Sells 115,118 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)Westfield Capital Management Co. LP lowered its stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 31.8% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 247,210 shares of the medical research companyMay 26, 2024 | americanbankingnews.comAnalyzing Bio-Rad Laboratories (NYSE:BIO) and Medtronic (NYSE:MDT)May 23, 2024 | businesswire.comBio-Rad's Management to Participate in Fireside Chat During Jefferies Global Healthcare ConferenceMay 23, 2024 | marketbeat.comBrown Advisory Inc. Cuts Position in Bio-Rad Laboratories, Inc. (NYSE:BIO)Brown Advisory Inc. lessened its holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 98.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 15,569 shares of the medical researchMay 23, 2024 | americanbankingnews.comBio-Rad Laboratories, Inc. (NYSE:BIO) Given Consensus Recommendation of "Moderate Buy" by AnalystsMay 23, 2024 | marketbeat.comBio-Rad Laboratories, Inc. (NYSE:BIO) Receives Average Rating of "Moderate Buy" from BrokeragesBio-Rad Laboratories, Inc. (NYSE:BIO - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the five research firms that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation and four have assigned a buy recomMay 22, 2024 | marketbeat.comING Groep NV Boosts Stake in Bio-Rad Laboratories, Inc. (NYSE:BIO)ING Groep NV increased its stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 5,200.0% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 6,466 shares of the medical research company's stock after purchasing an additional 6,344 sharesMay 21, 2024 | marketbeat.comGW&K Investment Management LLC Sells 6,921 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)GW&K Investment Management LLC reduced its stake in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 4.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 137,793 shares of the medical research company's stoMay 20, 2024 | marketbeat.comBio-Rad Laboratories, Inc. (NYSE:BIO) Shares Sold by Envestnet Portfolio Solutions Inc.Envestnet Portfolio Solutions Inc. cut its stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 50.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,551 shares of the medical research company's stocMay 18, 2024 | marketbeat.comBio-Rad Laboratories, Inc. (NYSE:BIO) Shares Acquired by BNP Paribas Financial MarketsBNP Paribas Financial Markets boosted its position in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 88.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 26,925 shares of the medical research cMay 15, 2024 | marketbeat.comJump Financial LLC Purchases Shares of 5,163 Bio-Rad Laboratories, Inc. (NYSE:BIO)Jump Financial LLC purchased a new position in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 5,163 shares of the medical reseMay 14, 2024 | markets.businessinsider.comPrecision BioSciences earnings: here's what Wall Street expectsMay 12, 2024 | marketbeat.comRoubaix Capital LLC Makes New $4.05 Million Investment in Bio-Rad Laboratories, Inc. (NYSE:BIO)Roubaix Capital LLC purchased a new position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 12,549 shares of the medical research comMay 11, 2024 | marketbeat.comMawer Investment Management Ltd. Cuts Stake in Bio-Rad Laboratories, Inc. (NYSE:BIO)Mawer Investment Management Ltd. reduced its stake in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 23.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 123,878 shares of the medical researcMay 10, 2024 | marketbeat.comNatixis Advisors L.P. Boosts Holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO)Natixis Advisors L.P. raised its stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 17.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 20,744 shares of theMay 9, 2024 | marketbeat.comSwiss National Bank Sells 3,400 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)Swiss National Bank lowered its stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 4.8% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 67,600 shares of the medical research company's stock after selling 3,400 shares during the periMay 8, 2024 | marketbeat.comBio-Rad Laboratories (NYSE:BIO) Releases Quarterly Earnings Results, Beats Expectations By $0.25 EPSBio-Rad Laboratories (NYSE:BIO - Get Free Report) released its earnings results on Tuesday. The medical research company reported $2.29 EPS for the quarter, beating the consensus estimate of $2.04 by $0.25. The firm had revenue of $610.82 million during the quarter, compared to analysts' expectations of $619.09 million. Bio-Rad Laboratories had a negative net margin of 23.86% and a positive return on equity of 3.90%. The business's quarterly revenue was down 9.8% compared to the same quarter last year. During the same period in the prior year, the company earned $3.34 EPS.May 8, 2024 | marketbeat.comBio-Rad Laboratories (NYSE:BIO) Price Target Cut to $385.00 by Analysts at UBS GroupUBS Group decreased their price objective on Bio-Rad Laboratories from $420.00 to $385.00 and set a "buy" rating for the company in a report on Wednesday.May 8, 2024 | finance.yahoo.comQ1 2024 Bio Rad Laboratories Inc Earnings CallMay 7, 2024 | markets.businessinsider.comBIO Stock Earnings: Bio-Rad Laboratories Beats EPS, Misses Revenue for Q1 2024May 7, 2024 | reuters.comBio-Rad Laboratories reiterates 2024 revenue growth outlook; shares slipMay 7, 2024 | businesswire.comBio-Rad Reports First-Quarter 2024 Financial ResultsMay 7, 2024 | marketbeat.comTruist Financial Corp Cuts Stock Position in Bio-Rad Laboratories, Inc. (NYSE:BIO)Truist Financial Corp trimmed its position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 21.5% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 11,635 shares of the medical research company's stock aftMay 5, 2024 | marketbeat.comFisher Asset Management LLC Sells 14,338 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)Fisher Asset Management LLC lowered its position in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 15.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 80,570 shares of the medical research company's stock after selling 14,33May 1, 2024 | finance.yahoo.comBio-Rad’s Management to Participate in Fireside Chat During RBC Capital Markets Global Healthcare ConferenceMay 1, 2024 | businesswire.comBio-Rad's Management to Participate in Fireside Chat During RBC Capital Markets Global Healthcare ConferenceApril 30, 2024 | marketbeat.comBio-Rad Laboratories (BIO) Scheduled to Post Earnings on TuesdayBio-Rad Laboratories (NYSE:BIO) will be releasing earnings after the market closes on Tuesday, May 7, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=586339)April 29, 2024 | marketbeat.comAnchor Capital Advisors LLC Sells 20,844 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)Anchor Capital Advisors LLC lowered its stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 21.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 76,698 shares of the mApril 28, 2024 | marketbeat.comIFM Investors Pty Ltd Makes New Investment in Bio-Rad Laboratories, Inc. (NYSE:BIO)IFM Investors Pty Ltd bought a new stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm bought 4,057 shares of the medical research company's stock, valued at approxApril 27, 2024 | marketbeat.comSector Gamma AS Makes New $7.62 Million Investment in Bio-Rad Laboratories, Inc. (NYSE:BIO)Sector Gamma AS bought a new position in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 23,609 shares of the medical research company's stock, valued at approximatelyApril 26, 2024 | businesswire.comBio-Rad Announces Life Science Group Management ChangesApril 23, 2024 | usatoday.comS&P 500 (SPX) today: Top movers are Bio-Rad Laboratories Inc and Agilent Technologies, Inc.April 22, 2024 | marketbeat.comBio-Rad Laboratories, Inc. (NYSE:BIO) Shares Bought by Duality Advisers LPDuality Advisers LP grew its position in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 431.6% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 8,564 shares of the medical research company's stock after acquiring an additional 6,953April 20, 2024 | marketbeat.comKornitzer Capital Management Inc. KS Cuts Holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO)Kornitzer Capital Management Inc. KS lessened its stake in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 9.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 36,647 shares ofApril 19, 2024 | nasdaq.comCommit To Purchase Bio-Rad Laboratories At $185, Earn 1.3% Annualized Using OptionsApril 18, 2024 | businesswire.comBio-Rad to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024April 17, 2024 | marketbeat.comBio-Rad Laboratories, Inc. (NYSE:BIO) to Post Q1 2025 Earnings of $2.39 Per Share, Zacks Research ForecastsBio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) - Investment analysts at Zacks Research upped their Q1 2025 earnings estimates for Bio-Rad Laboratories in a research report issued to clients and investors on Monday, April 15th. Zacks Research analyst R. Anand now forecasts that the medical reApril 16, 2024 | marketbeat.comZacks Research Equities Analysts Reduce Earnings Estimates for Bio-Rad Laboratories, Inc. (NYSE:BIO)Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) - Equities researchers at Zacks Research cut their Q1 2024 EPS estimates for Bio-Rad Laboratories in a research note issued to investors on Monday, April 15th. Zacks Research analyst R. Anand now anticipates that the medical research company wilApril 13, 2024 | marketbeat.comLecap Asset Management Ltd. Purchases New Position in Bio-Rad Laboratories, Inc. (NYSE:BIO)Lecap Asset Management Ltd. acquired a new position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm acquired 4,925 shares of the medical research company's stock, valued at approximately $1,590,0April 12, 2024 | marketbeat.comRaymond James & Associates Sells 21,649 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)Raymond James & Associates cut its holdings in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 62.3% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 13,083 shares of the medical research company's sto Get Bio-Rad Laboratories News Delivered to You Automatically Sign up to receive the latest news and ratings for BIO and its competitors with MarketBeat's FREE daily newsletter. Email Address Dems have chosen Biden replacement? (Ad)On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in the 2024 presidential election. See who it is HERE. BIO Media Mentions By Week BIO Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BIO News Sentiment▼0.480.79▲Average Medical News Sentiment BIO News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BIO Articles This Week▼175▲BIO Articles Average Week Get Bio-Rad Laboratories News Delivered to You Automatically Sign up to receive the latest news and ratings for BIO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Mettler-Toledo International News Waters News Illumina News Bio-Techne News Bruker News Charles River Laboratories International News Pacific Biosciences of California News Harvard Bioscience News aTyr Pharma News Thermo Fisher Scientific News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:BIO) was last updated on 6/1/2024 by MarketBeat.com Staff From Our PartnersThe #1 Crypto That You Don’t Own… YetCrypto 101 MediaDems have chosen Biden replacement?Paradigm PressBiden Nomination CANCELED?The Freeport SocietyNvidia is about to pass AppleWeiss RatingsClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProShocking: One AI startup's revenue could surge 4,735%Manward PressMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bio-Rad Laboratories, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
